BACKGROUND: The present study was designed to specifically investigate the clinicopathological role of expression of cortactin, as well as the correlation with clinical outcomes in stages II-III colorectal cancer (CRC). METHODS: Two hundred and five stages II-III CRC patients were included in this study. Formalin-fixed paraffin-embedded specimens were stained for cortactin and the correlation between the staining, its clinicopathological parameters, and its prognostic power were analyzed statistically. RESULTS: Of the 205 patients studied, 113 cases (55.1%) were strongly positive for cortactin. Cortactin expression correlated with tumor invasion (P = 0.018), histological grade (P = 0.004), and preoperative CEA level (P < 0.001). In univariate analysis, tumor invasion, American Joint Committee on Cancer (AJCC) stage, lymphovascular invasion, preoperative CEA level, and cortactin expression were significant prognostic factors for disease-free survival (P = 0.034, 0.009, 0.043, 0.004, and 0.004, respectively), while for overall survival, tumor invasion, AJCC stage, pathologic grade, preoperative CEA level, and cortactin expression were significant prognostic factors (P = 0.003, 0.008, 0.038, 0.017, and <0.001, respectively). In multivariate analysis, tumor invasion, preoperative CEA level, and cortactin expression maintained their independent prognostic influence on disease-free survival (P = <0.001, 0.003, and 0.008, respectively). However, tumor invasion, AJCC stage, and cortactin expression influenced overall survival (P = 0.036, <0.001, and 0.004, respectively). CONCLUSIONS: Cortactin may be a good biomarker to be applied in the clinical setting to predict the prognosis of patients with completely resected pathologic stages II-III CRC.
BACKGROUND: The present study was designed to specifically investigate the clinicopathological role of expression of cortactin, as well as the correlation with clinical outcomes in stages II-III colorectal cancer (CRC). METHODS: Two hundred and five stages II-III CRC patients were included in this study. Formalin-fixed paraffin-embedded specimens were stained for cortactin and the correlation between the staining, its clinicopathological parameters, and its prognostic power were analyzed statistically. RESULTS: Of the 205 patients studied, 113 cases (55.1%) were strongly positive for cortactin. Cortactin expression correlated with tumor invasion (P = 0.018), histological grade (P = 0.004), and preoperative CEA level (P < 0.001). In univariate analysis, tumor invasion, American Joint Committee on Cancer (AJCC) stage, lymphovascular invasion, preoperative CEA level, and cortactin expression were significant prognostic factors for disease-free survival (P = 0.034, 0.009, 0.043, 0.004, and 0.004, respectively), while for overall survival, tumor invasion, AJCC stage, pathologic grade, preoperative CEA level, and cortactin expression were significant prognostic factors (P = 0.003, 0.008, 0.038, 0.017, and <0.001, respectively). In multivariate analysis, tumor invasion, preoperative CEA level, and cortactin expression maintained their independent prognostic influence on disease-free survival (P = <0.001, 0.003, and 0.008, respectively). However, tumor invasion, AJCC stage, and cortactin expression influenced overall survival (P = 0.036, <0.001, and 0.004, respectively). CONCLUSIONS:Cortactin may be a good biomarker to be applied in the clinical setting to predict the prognosis of patients with completely resected pathologic stages II-III CRC.
Authors: J P Rodrigo; D García-Carracedo; L A García; St Menéndez; E Allonca; M V González; M F Fresno; C Suárez; J M García-Pedrero Journal: J Pathol Date: 2009-03 Impact factor: 7.996
Authors: Christopher J Ormandy; Elizabeth A Musgrove; Rina Hui; Roger J Daly; Robert L Sutherland Journal: Breast Cancer Res Treat Date: 2003-04 Impact factor: 4.872
Authors: P Hofman; C Butori; K Havet; V Hofman; E Selva; N Guevara; J Santini; E Van Obberghen-Schilling Journal: Br J Cancer Date: 2008-02-12 Impact factor: 7.640
Authors: J H Gibcus; M F Mastik; L Menkema; G H de Bock; Ph M Kluin; Ed Schuuring; J E van der Wal Journal: Br J Cancer Date: 2008-02-12 Impact factor: 7.640
Authors: Yujia Wen; Eric R Gamazon; Wasim K Bleibel; Claudia Wing; Shuangli Mi; Bridget E McIlwee; Shannon M Delaney; Shiwei Duan; Hae Kyung Im; M Eileen Dolan Journal: Hum Mol Genet Date: 2011-12-13 Impact factor: 6.150
Authors: Yo Na Kim; Ji Eun Choi; Jun Sang Bae; Kyu Yun Jang; Myoung Ja Chung; Woo Sung Moon; Myoung Jae Kang; Dong Geun Lee; Ho Sung Park Journal: Korean J Pathol Date: 2012-10-25
Authors: Claudia A Dumitru; Agnes Bankfalvi; Xiang Gu; Wilfried E Eberhardt; Reinhard Zeidler; Stephan Lang; Sven Brandau Journal: Front Immunol Date: 2013-02-18 Impact factor: 7.561